Minerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder
(Thomson Reuters ONE) -
WALTHAM, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
(NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the
development of therapies to treat central nervous system (CNS) disorders, today
announced the completion of patient enrollment in a randomized, placebo-
controlled double-blind European Phase IIa clinical trial of MIN-117 in major
depressive disorder (MDD).
The primary objective of this trial is to evaluate the efficacy of MIN-117
compared to placebo in reducing the symptoms of a major depressive episode as
measured by the change from baseline in the Montgomery-Asberg Depression Rating
Scale (MADRS) total score over six weeks of treatment. Additional objectives
include the assessment of onset to response, severity of illness, sexual
function, executive function, working memory, and safety and tolerability.
Eighty-four patients have been enrolled across the four treatment arms of this
study (0.5 and 2.5 mg daily of MIN-117, placebo, and 20 mg daily of paroxetine).
Top line results are expected in the second quarter of 2016.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in Phase
IIb development for schizophrenia; MIN-202 (JNJ-42847922), in Phase IIa and
Phase Ib development for insomnia and the adjunctive treatment of MDD,
respectively; MIN-117, in Phase IIa development for MDD; and MIN-301, in pre-
clinical development for Parkinson's disease. Minerva's common stock is listed
on the NASDAQ Global Market under the symbol "NERV." For more information,
please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that are not historical
facts, reflect management's expectations as of the date of this press release,
and involve certain risks and uncertainties. Forward-looking statements include
statements herein with respect to the timing and results of future clinical
milestones with MIN-117; the clinical and therapeutic potential of MIN-117; and
our ability to successfully develop and commercialize MIN-117. These forward-
looking statements are based on our current expectations and may differ
materially from actual results due to a variety of factors including, without
limitation, whether MIN-117 will advance further in the clinical trials process
and whether and when, if at all, it will receive final approval from the U.S.
Food and Drug Administration or equivalent foreign regulatory agencies and for
which indications; whether MIN-117 will be successfully marketed if approved;
whether our therapeutic product discovery and development efforts with MIN-117
will be successful; our ability to achieve the results contemplated by our co-
development agreements; management's ability to successfully achieve its goals;
our ability to raise additional capital to fund our operations on terms
acceptable to us; and general economic conditions. These and other potential
risks and uncertainties that could cause actual results to differ from the
results predicted are more fully detailed under the caption "Risk Factors" in
our filings with the Securities and Exchange Commission, including our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2015, filed with
the Securities and Exchange Commission on November 5, 2015. Copies of reports
filed with the SEC are posted on our website at www.minervaneurosciences.com.
The forward-looking statements in this press release are based on information
available to us as of the date hereof, and we disclaim any obligation to update
any forward-looking statements, except as required by law.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via GlobeNewswire
[HUG#1987740]
Datum: 22.02.2016 - 14:30 Uhr
Sprache: Deutsch
News-ID 452268
Anzahl Zeichen: 5067
contact information:
Town:
Waltham
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 228 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Minerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder"
steht unter der journalistisch-redaktionellen Verantwortung von
Minerva Neurosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
